NCT00126412View on ClinicalTrials.gov

Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma

PHASE3CompletedINTERVENTIONAL
Enrollment

251

Participants

Timeline

Start Date

August 2, 2005

Primary Completion Date

September 27, 2006

Study Completion Date

September 27, 2006

Conditions
PheochromocytomaNeuroblastoma
Interventions
DRUG

123I-mIBG (meta-iodobenzylguanidine)

Trial Locations (1)

08540

GE Healthcare, Princeton

Sponsors

Lead Sponsor

GE Healthcare
All Listed Sponsors
lead

GE Healthcare

INDUSTRY